EP1150718A1 - Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques - Google Patents

Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques

Info

Publication number
EP1150718A1
EP1150718A1 EP99935721A EP99935721A EP1150718A1 EP 1150718 A1 EP1150718 A1 EP 1150718A1 EP 99935721 A EP99935721 A EP 99935721A EP 99935721 A EP99935721 A EP 99935721A EP 1150718 A1 EP1150718 A1 EP 1150718A1
Authority
EP
European Patent Office
Prior art keywords
composition
matter
animal
tissue
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99935721A
Other languages
German (de)
English (en)
Inventor
Milton B. Yatvin
Michael B. Stowell
Michael J. Meredith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Original Assignee
Oregon Health Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University filed Critical Oregon Health Science University
Priority claimed from PCT/US1999/016361 external-priority patent/WO2000033884A1/fr
Publication of EP1150718A1 publication Critical patent/EP1150718A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine

Definitions

  • This invention is related to specific targeting of biologically-active compounds to specific cells, tissues and organs in vivo.
  • the invention specifically provides polar lipid conjugates of biologically-active compounds, particularly antibacterial, antibiotic, antiviral, antimycotic, antiproliferative and antineoplastic compounds, drugs and agents, and methods of effecting the uptake and accumulation of biologically active compounds into organs, tissues and cells, particularly at physiologically protected sites, at pharmicokinetically useful levels.
  • These polar lipid conjugates of this invention permit drug concentrations to be achieved, especially at physiologically protected sites, at levels at which such compounds are therapeutically effective after administration of systemic levels much lower than currently attainable otherwise.
  • This technology is appropriate for rapid and efficient introduction of antiproliferative, antineoplastic, antibiotic, antibacterial, antimycotic or antiviral drugs, agents and compounds, for example across the blood-brain barrier.
  • a major goal in the pharmacological arts has been the development of methods and compositions to facilitate the specific delivery of therapeutic and other agents to the appropriate organs, tissues and cells that would benefit from such treatment, and avoidance of the general physiological effects of the inappropriate delivery of such agents to other organs, tissues or cells in the body.
  • One common example of the need for such specificity is for introducing or administering biologically-active compounds, particularly antimicrobial, antiviral and antiproliferative and antineoplastic compounds, drugs or agents, into physiologically-protected reservoirs in an animal.
  • Examples of such protected sites include brain, central nervous system, eyes and testes, which are recognized as having physiological barriers (including endothelial cells and other structures) that inhibit transit of a variety of useful drugs into said reservoirs (for example, the blood-brain barrier) and into physiologically-restricted areas in vivo (such as lymph nodes). Avoiding general systemic side-effects is particularly important in administering biologically-active compounds targeted to such physiologically- protected sites, since achieving clinically useful concentrations of said compounds at these sites has frequently required administration of high systemic dosages which are associated with greater-than-acceptable levels of systemic toxicity.
  • physiological barriers including endothelial cells and other structures
  • Drug Targeting It is desirable to increase the efficiency and specificity of administration of a therapeutic agent in a variety of pathological states to the cells of the relevant organs and tissues protected by physiological barriers (i.e., such as the blood-brain barrier) and in physiologically-restricted areas in vivo (such as lymph nodes). This is particularly important as relates to antibiotic, antibacterial, antimycotic, antiviral, antiproliferative and antineoplastic drugs.
  • Such agents typically have systemic effects, including kidney and liver toxicity, hematopoietic suppression, teratogenic capacity, partitioning into breast milk and other pleiotropic cytotoxic effects that damage or otherwise deleteriously impact uninvolved organs, tissues and cells.
  • an additional challenge in designing an appropriate drug delivery scheme is to include within the drug conjugate a functionality which could either accelerate or reduce the rate at which the drug is released upon arrival at the desired site. Such a functionality would be especially valuable if it allowed differential rates of drug release, or specific release only at the appropriate drug target site comprising a specific organ, tissue or cell in a body.
  • U.S. Patent No. 5,023,252, issued June 11, 1991 to Hseih disclose the use of pharmaceutical compositions comprising a neurologically active drug and a compound for facilitating transport of said drug across the blood-brain barrier including a macrocyclic ester, diester, amide, diamide, amidine. diamidine, thioester, dithioester, thioamide, ketone or lactone.
  • U.S. Patent No. 5,124,146, issued June 23, 1992 to Neuwelt disclose a method for delivery of therapeutic agents across the blood-brain barrier at sites of increased permeability associated with brain lesions.
  • U.S. Patent No. 5,149,794, issued September 22, 1992 to Yatvin et al. disclose lipid conjugates with antineoplastic and antiviral drugs.
  • U.S. Patent No. 5,153,179, issued October 6, 1992 to Eibl disclose acylated glycerol and derivatives for use in a medicament for improved penetration of cell membranes.
  • U.S. Patent No. 5,177,064, issued January 5, 1993 to Bodor disclose the use of lipoidal phosphonate derivatives of nucleoside antiviral agents for delivery across the blood-brain barrier.
  • U.S. Patent 5,223,263, issued June 29, 1993 to Hostetler et al. disclose conjugates between antiviral nucleoside analogues and polar lipids, including phospholipids and ceramide.
  • U.S. Patent No. 5,254,342, issued October 19, 1993 to Shen et al. disclose receptor-mediated transcytosis of the blood-brain barrier using the transferrin receptor in combination with pharmaceutical compounds that enhance or accelerate this process.
  • U.S. Patent No. 5,270,312, issued December 14, 1993 to Glase et al. disclose substituted piperazines as central nervous system agents.
  • U.S. Patent No. 5,284,876, issued February 8, 1994 to Shashoua et al disclose fatty acid conjugates of dopanergic drugs for tardive dyskinesia.
  • U.S. Patent No. 5,389,623, issued February 14, 1995 to Bodor disclose the use of lipoidal dihydropyridine derivatives of antiinflammatory steroids or steroid sex hormones for delivery across the blood-brain barrier.
  • U.S. Patent No. 5,405,834, issued April 11, 1995 to Bundgaard et al. disclose prodrug derivatives of thyrotropin releasing hormone.
  • U.S. Patent No. 5,413,996, issued May 9, 1995 to Bodor disclose acyloxyalkyl phosphonate conjugates of neurologically-active drugs for anionic sequestration of such drugs in brain tissue.
  • U.S. Patent No. 5,434,137, issued July 18, 1995 to Black disclose methods for the selective opening of abnormal brain tissue capillaries using bradykinin infused into the carotid artery.
  • U.S. Patent No. 5,442,043, issued August 15, 1995 to Fukuta et al. disclose a peptide conjugate between a peptide having a biological activity and incapable of crossing the blood-brain barrier and a peptide which exhibits no biological activity and is capable of passing the blood-brain barrier by receptor-mediated endocytosis.
  • U.S. Patent No. 5,466,683, issued November 14, 1995 to Sterling et al. disclose water soluble analogues of the anticonvulsant Tegretol ® (carbamazepine) for the treatment of epilepsy.
  • U.S. Patent No. 5,484,809 issued January 16, 1996 to Hostetler et al. disclose taxol and taxol derivatives conjugated to phospholipids.
  • U.S. Patent No. 5,525,727 issued June 1 1, 1996 to Bodor disclose compositions for differential uptake and retention in brain tissue comprising a conjugate of a narcotic analgesic and agonists and antagonists thereof with a lipoidal form of dihydropyridine that forms a redox salt upon uptake across the blood-brain barrier that prevents partitioning back to the systemic circulation thereafter.
  • U.S. Patent No. 5,563,257, issued October 8, 1998 to Zilch et al. disclose nucleoside analogues conjugates to ether lipid moieties.
  • U.S. Patent No. 5,580,571, issued December 3, 1996 to Hostetler et al. disclose nucleoside analogues conjugated to phospholipids.
  • U.S. Patent No. 5,744,461, issued April 28, 1998 to Hostetler et al. disclose nucleoside analogues conjugated to phosphonoacetic acid lipid derivatives.
  • U.S. Patent No. 5,744,592, issued April 28, 1998 to Hostetler et al. disclose nucleoside analogues conjugated to phospholipids.
  • U.S. Patent No. 5,756,116, issued May 26, 1998 to Hostetler et al. disclose nucleoside analogues.
  • U.S. Patent No. 5,756,711, issued May 26, 1998 to Zilch et al. disclose nucleoside analogues conjugates to lipid moieties.
  • U.S. Patent No. 5,827,831, issued October 27, 1998 to Hostetler et al. disclose phospholipid-drug conjugates having enhanced gastrointestinal bioavailability.
  • the present invention is directed to improved methods for delivering biologically-active compounds, particularly drugs including preferably antibiotic, antibacterial, antimycotic, antiviral, antiproliferative and antineoplastic drugs, to specific organs, tissues and cells, most preferably comprising physiologically protected sites, in an animal in vivo.
  • This delivery system achieves specific delivery of biologically-active compounds by conjugating the compounds with a polar lipid carrier.
  • This invention has the specific advantage of effecting the delivery and accumulation of such compounds into particular organs, tissues and cells, most preferably wherein said organs, tissues and cells are protected by physiological barriers such as the blood-brain barrier, using a polar lipid carrier and thereby achieving effective concentration of such compounds more efficiently and with more specificity than conventional delivery systems.
  • compositions of matter comprising a biologically- active compound covalently linked to a polar lipid carrier molecule.
  • Preferred embodiments also comprise a spacer molecule having two linker functional groups, wherein the spacer has a first end and a second end each comprising a functional linker group, wherein the polar lipid is attached to the first end of the spacer through a first linker functional group and the biologically-active compound is attached to the second end of the spacer through a second linker functional group.
  • the biologically-active compound is a drug, most preferably an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative and antineoplastic drug or agent.
  • Preferred polar lipids include but are not limited to acyl- and acylated carnitine, sphingosine, ceramide, cardiolipin, and more preferably, phospholipids including phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, and phosphatidic acid, more particularly wherein said phospholipids have been deacylated at one of the two fatty acid-conjugated glycerol hydroxyl groups to produce a /yso-phospholipid having an unesterified glycerol hydroxyl for conjugation via a spacer moiety to a biologically active compound as provided by the invention.
  • Preferred biologically-active compounds include antibiotic, antibacterial, antimycotic, antiviral, antiproliferative and antineoplastic drugs.
  • the antiproliferative, antibiotic, antibacterial, antimycotic, antiviral or antineoplastic drug is covalently linked, either directly or via a spacer as disclosed herein, to a glycerol hydroxyl of a phospholipid, preferably phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, or phosphatidic acid.
  • the invention also provides pharmaceutical compositions comprising a biologically active compound conjugated with or without a spacer moiety to a polar lipid, preferably a phospholipid and most preferably to a /y-rophospholipid via a glycerol hydroxyl group, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
  • the invention also provides compositions of matter comprising a biologically-active compound covalently linked to a lipid carrier molecule, most preferably a polar lipid via a spacer molecule wherein the spacer allows the biologically-active compound to act without being released in an organ, tissue or cell.
  • the first linker functional group attached to the first end of the spacer is characterized as "strong” and the second linker functional group attached to the second end of the spacer is characterized as "weak", with reference to the propensity of the covalent bonds between each end of the spacer molecule to be broken.
  • the spacer allows the specific hydrolytic or enzymatic release of the biologically- active compound at a particular organ, tissue or cellular site.
  • enzymatic release is mediated by a cellular phospholipase, preferably phospholipase A, or A 2 , wherein drug-acyl chain conjugates are cleaved at the ester bond between an acyl moiety comprising the spacer and the glycerol hydroxyl.
  • the spacer functional group is hydrolyzed by an enzymatic activity found in a specific organ, tissue or cell type, more preferably in an organ or tissue comprising a physiologically protected site including brain, central nervous system, eyes, testes and lymph nodes.
  • the spacer functional group is hydrolyzed by an enzymatic activity found in brain tissue, including neuronal, glial and other brain cell types, preferably an esterase or lipase and most preferably an esterase or lipase having a differential expression and activity profile in the appropriate target cell type.
  • specific release of biologically-active compounds is achieved by enzymatic or chemical release of the biologically-active compound by extracellular cleavage of a cleavable linker moiety via an enzymatic activity specific for a particular organ, tissue or cell type, more preferably in an organ or tissue comprising a physiologically protected site, and most preferably brain tissue, with resulting specific uptake of the released antiproliferative, antibiotic, antibacterial, antimycotic, antiviral or antineoplastic drug or agent by the appropriate cell in said tissue.
  • the spacer molecule is a peptide of formula (amino acid),,, wherein n is an integer between 2 and 25, preferably wherein the peptide comprises a polymer of one or more amino acids.
  • the biologically-active compound of the invention has a first functional linker group, and a polar lipid carrier, most preferably a phospholipid carrier, has a second functional linker group, preferably a hydroxyl group and most preferably a glycerol hydroxyl group of a phospholipid, wherein the compound is covalently linked directly to the lipid carrier by a chemical bond between the first and second functional linker groups.
  • each of the first and second functional linker groups is a hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.
  • compositions of matter comprising a drug, most preferably an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug or agent, covalently linked to a polar lipid carrier molecule.
  • antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs or agents having a first functional linker group, and a polar lipid carrier having a second functional linker group, wherein the drug is covalently linked directly to the polar lipid carrier by a chemical bond between the first and second functional linker groups.
  • each of the first and second functional linker groups is a hydroxyl group, most preferably a glycerol hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.
  • Preferred polar lipids include but are not limited to acyl- and acylated carnitine, sphingosine, ceramide, cardiolipin, and more preferably, phospholipids including phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, and phosphatidic acid, more particularly wherein said phospholipids have been deacylated at one of the two fatty acid-conjugated glycerol hydroxyl groups to produce a /ys ⁇ -phospholipid having an unesterified glycerol hydroxyl for conjugation with a drug as provided by the invention.
  • the antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug is covalently linked directly to a phospholipid, more preferably to a glycerol hydroxyl of a phospholipid, most preferably wherein the phospholipid comprises a lyso form of phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, or phosphatidic acid.
  • the invention also provides pharmaceutical compositions comprising said antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs conjugated with or without a spacer moiety to a polar lipid, most preferably a phospholipid, in a pharmaceutically acceptable carrier.
  • compositions of matter comprising an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug covalently linked directly to phospholipid and most preferably to a glycerol hydroxyl of said phospholipid, wherein the covalent linkage allows the drug to act without being released at an organ, tissue or cellular site.
  • the covalent linkage allows the specific hydrolytic or enzymatic release of an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug or agent at a particular organ, tissue or cellular site.
  • an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug or agent at a particular organ, tissue or cellular site.
  • One non-limiting example of such enzymatic release is mediated by a cellular phospholipase, preferably phospholipase A, or A 2 , wherein the drug is cleaved at the ester bond between an acyl moiety comprising the drug and the glycerol hydroxyl.
  • the cleavage is mediated by a hydrolytic or enzymatic activity found in a specific organ, tissue or cell type, more preferably in an organ or tissue comprising a physiologically protected site including brain, central nervous system, eyes, testes and lymph nodes.
  • the spacer functional group is hydrolyzed by an enzymatic activity found in brain tissue, including neuronal, glial and other brain cell types, wherein said enzymatic activity is preferably an esterase or lipase and most preferably an esterase or lipase having a differential expression and activity profile in different tissue cell types.
  • specific release of the antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug or agent of the invention is achieved by enzymatic or chemical release of these drugs by extracellular cleavage of the drug-lipid covalent linkage, preferably via an enzymatic activity specific for, for example, brain tissue, followed by specific uptake of the released antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug by the appropriate cell in said tissue.
  • the invention comprehends a polar lipid conjugate with a biologically active compound wherein the polar lipid selectively promotes delivery to or preferential accumulation in particular organs, tissues or cells in an animal in vivo.
  • the invention provides said polar lipid- drug conjugates that promote association with and transit across certain physiological barriers to organs, tissues or cells comprising physiologically protected sites.
  • the biologically active compounds are drugs, more preferably antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs.
  • the invention preferably provides specific delivery or accumulation of said polar lipid-drug conjugates to said physiologically restricted or protected sites.
  • the spacer component of the conjugates of the invention will preferably act to specifically release the drug from the lipid at the target site; prevent the non-specific release from the drug from the lipid in the systemic circulation or in hematopoietic, hepatic, renal or other inappropriate cells, tissues or organs; target the conjugate to a specific cell or cell type within the protected tissue; prevent interaction and/or uptake of the drug by hematopoietic, ocular, hepatic or renal tissues; or perform other functions to maximize the effectiveness of the drug.
  • the polar lipid conjugates of the invention provide delivery or preferential accumulation of a variety of biologically active compounds, preferably antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs and agents, to organs, tissues or cells, most preferably physiologically restricted or protected sites in vivo at concentrations and pharmicokinetic rates not heretofore attainable.
  • a benefit of this advantage is the achievement of therapeutic indices of agents in such protected sites whereby the agent is useful for achieving a desired therapeutic goal.
  • Another benefit is decreased hepatic toxicity, hematopoietic suppression (such as thrombocytopenia, leukopenia, aplastic anemia, leukocytosis, eosinophilia, pancytopenia, agranulocytosis), reduced systemic metabolism, degradation and toxicity, reduced hepatic clearance, reduced systemic adverse drug interactions, and generally reduced side effects due to the achievement of a lower, therapeutically- effective dose as the result of surmounting the physiological barrier.
  • hematopoietic suppression such as thrombocytopenia, leukopenia, aplastic anemia, leukocytosis, eosinophilia, pancytopenia, agranulocytosis
  • reduced systemic metabolism degradation and toxicity
  • reduced hepatic clearance reduced systemic adverse drug interactions
  • side effects can also result in simplified dosage schedules, particularly for drugs with short systemic half-lives.
  • the polar lipid conjugates of the invention incorporate a variable spacer region that may allow pharmacologically- relevant rates of drug release from polar lipid carrier molecules to be engineered into the compositions of the invention, thereby increasing their clinical efficacy and usefulness.
  • time-dependent drug release and specific drug release in organs, tissues and cells expressing the appropriate degradative enzymes are a unique possibility using the polar lipid conjugates of the invention.
  • antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug/spacer/polar lipid conjugates can provide an in vivo reservoir of time-dependent drug release in a specific organ, tissue or cell, preferably comprising a physiologically protected site, resulting in specific delivery of therapeutic amounts to such tissues using a reduced dosage regime to minimize non-specific, systemic and deleterious side effects.
  • the amount and activity of the antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug can be modulated by release via cleavage, preferably hydrolytic cleavage, of the spacer moiety, most preferably by an enzymatic activity in the organ, tissue or cell, most preferably comprising a physiologically protected tissue (e.g., brain) that has a differential pattern of expression or activity in different cell types in said tissue or systemically.
  • cleavage preferably hydrolytic cleavage
  • the spacer moiety most preferably by an enzymatic activity in the organ, tissue or cell, most preferably comprising a physiologically protected tissue (e.g., brain) that has a differential pattern of expression or activity in different cell types in said tissue or systemically.
  • a physiologically protected tissue e.g., brain
  • Figure 1 depicts the structure of the AE 6 PC compound of the invention.
  • Figure 2 depicts the synthetic scheme for producing the AE 6 PC compound of the invention.
  • Figure 3 depicts the structure of the AE 6 C compound of the invention.
  • Figure 4 depicts the synthetic scheme for producing the AE 6 C compound of the invention.
  • Figure 5A depicts a comparison of brain uptake of AZT and the AE 6 PC and AE 6 C compounds of the invention in fasted mice orally intubated and administered 0.5mL of 7.5mM AZT, AE 6 C or AE 6 PC in FBS.
  • Figure 5B depicts a comparison of brain uptake of AZT and the AE 6 PC and AE 6 C compounds of the invention in mice intravenously injected with 0.5mL of 7.5mM AZT, AE 6 C or AE 6 PC in a pharmaceutically-acceptable carrier.
  • Figure 6 depicts a comparison of testes uptake of AZT and the AE 6 PC and NE 6 C compounds of the invention in fasted mice orally intubated and administered 0.5mL of 7.5mM AZT, AE 6 C or AE 6 PC in FBS.
  • Figures 7A through 7E depict a comparison of infection of NIH 3T3 cells in culture over a 24h period with a Mo-MuLN derived human growth hormone recombinant expression construct in the presence of 0.25mM AZT, AE 6 PC or AE 6 C, or ddl, IE 6 PC or IE 6 C
  • Figures 8A through 8C depict methotrexate-polar lipid conjugates of the invention.
  • Figures 9A and 9B illustrate synthetic schemes for producing Mtx salicylate esters conjugated to sphingosine.
  • the present invention provides compositions of matter, pharmaceutical compositions and methods for achieving specific delivery to and accumulation of biologically-active compounds into organs, tissues and cells, most preferably organs, tissues and cells comprising physiologically-protected sites in an animal.
  • biologically-active compound is intended to encompass all naturally-occurring or synthetic compounds capable of eliciting a biological response or having an effect, either beneficial or cytotoxic, on biological systems, particularly cells and cellular organelles. These compounds are intended to include but are not limited to all varieties of drugs, particularly antiproliferative drugs and agents, antimicrobial drugs, including antibacterial, fungicidal, anti-protozoal and antiviral drugs, antineoplastic drugs, and cytotoxic and cytostatic compounds.
  • the invention provides polar lipid conjugates comprising antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and compounds.
  • the invention provides said antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and compounds wherein said drugs, agents and compounds are linked to a polar lipid compound via a cleavable linker moiety.
  • antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs and agents are intended to include any drug, agent or compound having an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic effect in an animal, preferably a human.
  • antimicrobial drug will be understood to encompass said antibiotic, antibacterial, antimycotic, and antiviral compounds, as well as other compounds that have an antimicrobial effect (such as anti-plasmodial drugs).
  • antimicrobial drug is intended to encompass any pharmacological agent effective in inhibiting, attenuating, combating or overcoming infection of mammalian cells by a microbial pathogen in vivo or in vitro.
  • Antimicrobial drugs as provided as components of the antimicrobial agents of the invention include but are not limited to penicillin and drugs of the penicillin family of antimicrobial drugs, including but not limited to penicillin-G, penicillin-N, phenethicillin, ampicillin, amoxacillin, cyclacillin, bacampicillin, hetacillin, cloxacillin, dicloxacillin, methicillin, nafcillin, oxacillin, azlocillin, carbenicillin, mezlocillin, piperacillin, ticaricillin, and imipenim; cephalosporin and drugs of the cephalosporin family, including but not limited to cefadroxil, cefazolin, caphalexn, cephalothin, cephapirin, cephradine, cefaclor, cefamandole, cefonicid, cefoxin, cefuroxime, ceforanide, cefotetan, cefmetazole, cef
  • 201 23-31
  • others provided as naturally-occurring, chemically synthesized in vitro or produced as the result of engineering to make such peptides resistant to the action of pathogen-specific proteases and other deactivating enzymes; other antimicrobial drugs, including chloramphenicol, vancomycin, rifampicin, metronidazole, ethambutol, pyrazinamide, sulfonamides, isoniazid, and erythromycin.
  • other antimicrobial drugs including chloramphenicol, vancomycin, rifampicin, metronidazole, ethambutol, pyrazinamide, sulfonamides, isoniazid, and erythromycin.
  • Antiviral drugs including but not limited to reverse transcriptase inhibitors, protease inhibitors, antiherpetics such as acyclovir and gancyclovir, azidothymidine (3'azido, 3'-deoxythymidine, Zidovudine, AZT), dideoxyinosine (Didanosine, ddl), dideoxycytidine (Zalcitabine, ddC), cytidine arabinoside, ribavirin, amantadine, iododeoxyuridine, foscarnet, trifluoridine, methizazone, vidarabine and levanisole are also encompassed by this definition and are expressly included therein.
  • Antimycotic drugs provided by the invention and comprising the pharmaceutical compositions thereof include but are not limited to clotrimazole, nystatin, econazole and myconixole, ketoconazole, grisefulvin, ciclopixox, naftitine and other imidizole antimycotics.
  • Antiproliferative and antineoplastic agents provided by the invention and comprising the pharmaceutical compositions thereof include but are not limited to methotrexate, doxarubicin, daunarubicin, epipodophyllotoxins. 5-fluorouracil, tamoxifen, actinomycin D, vinblastine, vincristine, colchicine and taxol.
  • the invention also provides antibiotic drugs and agents wherein an antimicrobial agent is a toxin capable of specific cytotoxicity against the microbe, its host cell or both.
  • an antimicrobial agent is a toxin capable of specific cytotoxicity against the microbe, its host cell or both.
  • toxin is intended to encompass any pharmacological agent capable of such toxicity, including for example ricin from jack bean, diphtheria toxin, and other naturally-occurring and man-made toxins.
  • Appropriate formulations and pharmaceutical compositions of the antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug/ polar lipid conjugates of the invention will be apparent and within the skill of one of ordinary skill in this art to advantageously prepare in view of the instant disclosure.
  • said pharmaceutical compositions are provided for topical application, comprising appropriately chosen salves, ointments and emollients.
  • said topical application is specifically adapted for administration to ocular tissues, comprising electrolytically balanced solutions for topical and direct administration to vertebrate, preferably mammalian and most preferably human eyes.
  • the pharmaceutical composition comprises complexes formed for example with serum albumin, polyvinylpyrrolidone and other pharmaceutically acceptable carriers and excipients for parenteral administration, including but not limited to intravenous, intramuscular, and subcutaneous routes of administration.
  • the pharmaceutical compositions of the invention are provided to be orally bioavailable by administration in tablets, capsules, elixirs, gums, and other formulations comprising excipients adapted for transit of the conjugates of the invention through the gastrointestinal tract. Oral and parenteral routes of administration are preferred.
  • the polar lipid conjugates are provided wherein the biologically active compound is in a form having reduced, inhibited, or essentially no biological activity and wherein this form of the compound is capable of being converted by chemical or enzymatic means, most preferably in vivo, into a form having a desired biological activity; when the biologically active compound is a drug, this form of the drug is commonly termed a "prodrug.”
  • prodrugs useful in the present invention include prodrugs that can be converted by chemical or enzymatic means in a targeted organ, tissue or cell in an animal.
  • said prodrugs are converted into a form having a desired biological activity in an organ or tissue extracellularly, i.e. within the physical and anatomically-recognized province of the organ or tissue but not within any particular cell in the organ or tissue.
  • the activated prodrug is then capable of having the desired biological activity without entry into any particular cell comprising said organ or tissue.
  • the activated prodrug is then capable of entering a cell comprising said organ or tissue and having the desired biological activity thereof.
  • the prodrug is only converted into the active form after entry into a particular cell or cell type comprising said organ or tissue.
  • the terms "chemic-. PCT/US99/163 1 encompass chemical conditions (including but not limited to salt or other electrolyte concentration, metabolite concentration. pH. osmolality. osmolarity. dielectric constant, temperature, pressure, or chemical catalyst concentration) or presence of enzymatic activity (including but not limited to esterases. amidases. peptidases, nucleases, peroxidases, lipases. or redox proteins) in an organ, tissue or cell, most preferably in a physiologically-protected site in an animal, most preferably a human.
  • spacer moiety comprising any particular embodiment of the pharmaceutical compositions or compositions of matter of the invention, and particularly the choice of said linker functional groups comprising said spacer moieties, is chosen to match the chemical or enzymatic means present in the organ, tissue or cell targeted by said composition.
  • compositions of matter and pharmaceutical compositions provided by the invention comprise biologically-active compounds covalently linked to a polar lipid carrier.
  • a polar lipid carrier as defined herein is intended to mean any polar lipid that is delivered to. or preferentially accumulates in. an organ, tissue or cell in an animal.
  • the polar lipid conjugates have an affinity for, or are capable of crossing, a biological membrane and in particular a physiological barrier protecting certain cells, tissues and organs in an animal body.
  • Polar lipid carriers encompassed by this invention include but are not limited to sphingosine. sphingomyelin and other sphingolipids. ceramide and cardiolipin, and more preferably, phospholipids.
  • phosphatidyl choline phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol. phosphatidyl serine, and phosphatidic acid, and more particularly wherein said phospholipids have been deacylated at one of the two fatty acid-conjugated glycerol hydroxyl groups to produce a /Ys ⁇ -phospholipid having an unesterified glycerol hydroxyl for conjugation with a biologically active compound as provided by the invention, as these terms are understood in the art (see. Lehninger, Biochemistry. 2d ed.. Chapters 1 1 & 24, Worth Publishers: New York.
  • lipids such as acylated carnitine.
  • conjugates of the invention see Small. 1986, “From alkanes to phospholipids," Handbook of Lipid Research: Physical Chemistry of Lipids, Volume 4, Chapters 4 and 12. Plenum Press: New York).
  • polar lipid is not intended to encompass “lipoid " -type compounds, such as. for example, aliphatic phosphonates (see. for example. U.S. Patent No. 5.413.996).
  • compositions of matter and pharmaceutical compositions of the invention may further comprise a spacer moiety comprising a first end and a second end. each end of the spacer having a functional linking group.
  • spacer or “spacer moiety” is intended to encompass any chemical entity that links a biologically-active compound and a polar lipid compound according to the invention.
  • spacer moieties may be designed to promote or effect the delivery to or accumulation at specific organs, tissues or cells, or to promote, influence, modulate or regulate the release of the biologically-active compound at the desired target site.
  • Such spacers may facilitate enzymatic release at specific organs, tissues and cell, preferably at extracellular sites therein: more preferably, said spacers inhibit enzymatic.
  • Spacer groups include, but are not limited to aminohexanoic acid, adipic acid, and other bifunctional organic acids; peptides including homopolymers such as polyglycine: substituted fatty acids; carbohydrate moieties including mono-, di- and other saccharides: oligonucleotides; polyamides, polyethylenes. and short functionalized polymers having a carbon backbone which is from one to about twelve carbon molecules in length. Particularly preferred embodiments of such spacer moieties comprise peptides of formula (amino acid) n .
  • linker functional group is defined herein as any functional group for covalently binding the polar lipid carrier or biologically-active agent to the spacer group. These groups can be designated either “weak” or “strong” based on the stability of the covalent bond which the linker functional group will form between the spacer and either the polar lipid carrier or the biologically- active compound.
  • the weak functionalities include, but are not limited to phosphoramide, phosphoester. carbonate, amide, carboxyl-phosphoryl anhydride, thioester and most preferably ester.
  • the strong functionalities include, but are not limited to ether, thioether, amine, amide and most preferably ester.
  • the use of a strong linker functional group between the spacer group and the biologically- active compound will tend to decrease the rate at which the compound will be released at the target site, whereas the use of a weak linker functional group between the spacer group and the compound may act to increase the release rate of the compound at the target site.
  • Enzymatic release is, of course, also possible, but such enzyme-mediated modes of release will not necessarily be correlated with bond strength in such embodiments of the invention.
  • Spacer moieties comprising enzyme active site recognition groups, such as spacer groups comprising peptides having proteolytic cleavage sites therein, are envisioned as being within the scope of the present invention.
  • such specifically- cleavable peptides are preferably prepared so as to be recognized by enzymes present in particular organs or tissues such as brain and other physiologically restricted or protected sites in vivo, so that the drug is preferentially liberated from the polar lipid conjugate at appropriate drug delivery sites.
  • An illustrative example of such a specifically-cleavable peptide is a portion of the proopiomelanocortin family of peptides, which are cleaved in mammalian brain tissue to release a variety of peptides hormones and effector molecules, such as the enkephalins.
  • Other beneficial and advantageous specifically-cleavable peptides will be recognized by those of ordinary skill in the art.
  • the linker functional groups are selected to inhibit or prevent cleavage of the covalent linkage between the spacer and the biologically active compound, or between the spacer and the polar lipid carrier, at a site other than the specific site to which the conjugate is targeted.
  • the polar lipid conjugates of the invention are also preferably provided comprised of spacer moieties that impart differential release properties on the conjugates related to differential expression or activity of enzymatic activities in specific organs, tissues or cells in comparison with such activities in systemic circulation or in inappropriate targets, such as hepatic, renal or hematopoietic tissues.
  • said organs, tissue and cells comprise physiologically restricted or protected sites in vivo. Differential release is also provided in certain embodiments in specific cell types comprising such physiologically protected tissues, for example, in different cell types (neuronal, glial, etc.) in brain tissue.
  • the polar lipid conjugates of the invention are provided for targeting said conjugates to specific organs, tissues and cells in an animal.
  • the conjugates are targeted to eye, spleen, lung, testes and the central nervous system, most preferably the brain.
  • antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug/polar lipid conjugates for specific delivery to or accumulation in specific organs, tissues and cells in an animal.
  • the polar lipid/drug conjugates are targeted to the central nervous system, most preferably brain tissue, for the alleviation or amelioration of pathological disease states therein.
  • polar lipid/drug conjugates for facilitating the transit of the polar lipid conjugates of antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and compounds across the blood-brain barrier and into targeted regions of the brain, for the treatment of animal, preferably human, diseases and pathological conditions.
  • Among the most common such diseases and conditions are acquired immune deficiency syndrome, neuroblastoma, glioma, astrocytoma, meningioma, sarcoma, metastatic melanoma, metastatic adenocarcinoma, syphilis, encephalitis, meningitis, nocardiosis, abscess, coccidiodomycosis, cryptococcosis, subdural empyema, extrapulmonary tuberculosis, leptospirosis, toxoplasmosis, trichinosis, trypanosomiasis, mycoplasma infection, herpetic encephalitis, and schistosomiasis.
  • polar lipid/drug conjugates of polar lipids and antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and compounds for delivery to or accumulation in lung tissue or spleen tissue wherein said conjugates particularly comprise salicylic acid esters between the polar lipid and the drug.
  • the compound is the ceramide N-(methotrexate)-N- (6aminocaproyl(salicylate) sphingosine ester.
  • lung tumors such as adenocarcinoma, small cell carcinoma, and other tumors of the lung
  • tuberculosis bronchitis
  • emphysema emphysema
  • pneumonia cystic fibrosis
  • Gaucher's disease emphysema
  • other diseases and disorders of lung or spleen tissue emphysema
  • the invention specifically provides methods for preparing and administering biologically active compounds, most preferably antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and compounds for use in treating pathological conditions in vivo.
  • Said methods include but are not limited to parenteral methods, such as intravenous, intramuscular and subcutaneous injection; oral methods, including administration of pills, tablets, elixirs, capsules and other formulations; topical administration, including ointments, salves, poultices and the like, particularly including solutions specifically adapted for topical administration to the eye; and rectal administration, including suppositories, enemas and other appropriate formulations. Oral and parenteral routes of administration are preferred.
  • Animals to be treated with the polar lipid conjugates of biologically active compounds according to the invention using the methods disclosed herein are intended to include all vertebrate animals, preferably domesticated animals, such as cattle, horses, goats, sheep, fowl, fish, household pets, and others, as well as wild animals, and most preferably humans.
  • a polar lipid conjugate with azidothymidine was prepared by conjugating an adipic acid linker moiety to a polar lipid via an ester linkage, as follows. The structure of this conjugate is shown in Figure 1, and the synthetic scheme is shown in Figure 2.
  • a polar lipid (lysophosphatidylcholine) comprising unesterified hydroxyl groups was reacted with an activated adipic acid monomethylester (AMME) in the presence of 1.0 equivalent of dicyclohexyl carbodiimide (DCCD) overnight at 40-50°C at pH 6.5-7.5.
  • AMME activated adipic acid monomethylester
  • the derivatized lysophosphatidylcholine was then reacted with 0.1N methanolic potassium hydroxide at room temperature, and optionally then treated with 2.0 equivalents of tert-butyl dimethyl silyl imidazole (TBDMS) overnight at 40-50°C.
  • TDMS tert-butyl dimethyl silyl imidazole
  • This lysophosphatidylethanolamine species derivatized by an ester linkage between the glycerol hydroxyl group of lysophosphatidylethanolamine and the 1- carboxylate group of adipic acid, was then esterified at the 7-carboxylate group of the adipic acid spacer with azidothymidine and DCCD overnight at 40-50°C.
  • the azidothymidine-phosphatidylethanolamine conjugate was then deprotected, if appropriate, by treatment with 4.0 equivalents of t-butylammonium fluoride at 0°C for 10 minutes. Side products of the synthetic reaction are removed using conventional chemical purification techniques. Synthesis of conjugates comprising ester linkages advantageously permits control of rates of drug release based on differences in amount and rates of esterase enzymatic activity in the brain.
  • a polar lipid conjugate of azidothymidine comprising an ester linkage is prepared by conjugating a linker moiety to a polar lipid via an amide linkage, as follows. The structure of this conjugate is shown in Figure 3, and the synthetic scheme is shown in Figure 4.
  • a polar lipid (sphingosine) comprising unconjugated amino groups was reacted with a activated adipic acid monomethyl ester (AMME) in the presence of 1.0 equivalent of dicyclohexyl carbodiimide (DCCD) overnight at 40-50°C.
  • AMME activated adipic acid monomethyl ester
  • the derivatized sphingosine was then reacted with 0.1N methanolic potassium hydroxide at room temperature, and then treated with 2.0 equivalents of tert-butyl dimethyl silyl imidazole (TBDMS) overnight at 40-50°C.
  • TDMMS tert-butyl dimethyl silyl imidazole
  • This sphingosine species, derivatized by an amide linkage between the amino group of sphingosine and the 1 -carboxylate group of AMME was then esterified at the 7-carboxylate group of unprotected adipic acid with azidothymidine and DCCD overnight at 40-50°C.
  • Frozen tissues were weighed, thawed and then homogenized at 0-4°C in a volume (in mL) of 0.5% sodium ascorbate equal to three times the weight of the tissue in grams. The homogenate was then centrifuged at 16,000g for 15min. The resulting supernatant was boiled for 5 min in a DB-1 Dry Block Heater, and the pellet was resuspended in lmL of 0.5% sodium ascorbate. After these treatments, both the pellet fraction and the supernatant fraction were centrifuged at 16,000g for 15 min. A small pellet was recovered from the centrifuged supernatant.
  • the supernatant from the boiled supernatant fraction was decanted from the pellet into a fresh test tube, and the volume noted.
  • the supernatant from the centrifuged pellet fraction was decanted from the pellet and added to the fresh test tube containing the supernatant fraction, and the two supernatant fractions mixed by vortexing.
  • the volume of the mixed supernatant was reduced to the original volume of the supernatant fraction supernatant by bubbling nitrogen gas therethrough at 37°C.
  • the reduced supernatant fraction was then stored at -20°C.
  • the pellet fractions were mixed and extracted three times with lmL anhydrous methanol.
  • the amount detected after 24 hr remained at about 53% of the peak value detected at 4hr in spleen (32-fold higher than unconjugated AZT), at about 37% of the peak value detected at 2hr in brain (129-fold higher than unconjugated AZT), at about 20% of the peak value detected at 2hr in thymus (48-fold higher than unconjugated AZT), and at about 4% of the peak value detected at 2hr in testes (34-fold higher than unconjugated AZT).
  • the amount detected after 24 hr remained at about 21%) of the value detected at 2hr in spleen (34-fold higher than unconjugated AZT), at about 32% of the value detected at 2hr in brain (109-fold higher than unconjugated AZT), at about 14% of the value detected at 2hr in thymus (33-fold higher than unconjugated AZT), and at about 5% of the value detected at 2hr in testes (21 -fold higher than unconjugated AZT).
  • Table IB compares the results of testicular uptake of AZT, AE 6 C and AE 6 PC in fasted mice where the drug was administered by oral intubation as above, or by intravenous (IN) injection of fed mice with 0.5mL of a 7.5mM solution of each of the drugs or drug conjugated in a acceptable injection vehicle. The results obtained with IN injection are consistent with the results obtained TABLE IA
  • Table IA The results shown in Table IA are represented graphically in Figures 5A and 5B (for brain) and 6 (for testes).
  • Figure 5A graphically represents the data presented in Table IA, and demonstrates that both AE 6 C and AE 6 PC reach higher concentrations and persist longer in brain tissue that AZT alone when administered by oral intubation.
  • AE 6 PC is eliminated very slowly in brain. Twenty-four hours after drug administration, the concentration of this drug conjugate remains more than 100-fold higher than AZT itself.
  • An additional advantage of AE 6 PC over AE 6 C in these studies is its higher solubility in water-based solutions, which may be important for clinical use.
  • Figure 5B shows the results of brain uptake and accumulation experiments performed by intravenous administration of AZT, AE 6 PC and AE 6 C, as described above regarding testes-specific uptake and accumulation of these drugs. These results show enhanced accumulation of the polar lipid drug conjugates in brain tissue, and at higher absolute amounts of the compounds (compare the units on the y axes of Figures 5A and 5B). These graphic representations also illustrate that both conjugated compounds are found at essentially equivalent and much higher levels in brain that unconjugated AZT, and that much more of all three compounds are found in testes than in brain (compare the scale of the ordinate). In addition, all three compounds are cleared from testes between 4 and 8 hr, with levels of all three compounds remaining essentially the same between 8 and 24 hr in testes.
  • NIH 3T3 cells were exposed to l ⁇ M AZT or AE 6 C for two hours and then infected with the HgH-encoding recombinant viral construct 6h, 12h or 24h after removal of the drug.
  • AE 6 C was shown to suppress viral growth better than AZT at 12 and 24 hours after drug removal. It is important to note that viral growth was suppressed even 24 hours after removal of AE 6 C. This suggested that this prodrug had saturated the cellular lipid phase, releasing active drug many hours after removal.
  • AZT-treated cultures showed greater viral infection levels than controls.
  • Figure 7B shows results of a comparison between ddl and the ddl prodrug, IE 6 C.
  • This prodrug was made using synthetic chemistries similar to those disclosed in Example 2 for AZT conjugates. Cells were incubated for 2 hours in 0.375 ⁇ M ddl or IE 6 C, the drug removed and the cells infected with the recombinant viral construct Oh, 12h, 24h, and 48h thereafter.
  • the results presented in Figure 7B show that the ddl prodrug was most efficient at inhibiting recombinant virus expression 12 hours following the removal of the drug. The prodrug continued to suppress viral infection even 24 hr after removal of the prodrug. Free ddl was not able to prevent reinfection.
  • FIG. 7C shows the results of studies in which cells were grown in medium containing 0.25 ⁇ M AZT, AE 6 C or AE 6 PC for four days. The drug containing medium was then removed either 12, 24 or 48 hours prior to virus infection. The drug and virus treatments were staggered to ensure that all cells were simultaneously infected with the same batch of virus. Following a two-hour exposure to virus, cells were reincubated for 20 hour in medium free of both drugs and virus. Cells were then assayed for HgH content by RIA. Prodrug was found to inhibit recombinant virus infection even 48h after removal of the prodrug from the cell culture medium.
  • AZT on the other hand, was associated with an increase in virus infection 48h after removal of the drug.
  • the prolonged antiviral action of the prodrugs was not unexpected because the prodrugs readily entered the cells, were retained for prolonged periods of time, maintaining stable intracellular drug pools, although the effect of AZT was unexpected.
  • prodrug-treated cells were slightly more resistant to infection.
  • these results show that not only were ddl and AZT not able to prevent viral infection, but both ddl- and AZT-treated cells were more sensitive to infection than control cells.
  • Cells pretreated with prodrug were better protected against infection for longer periods of time after drug removal from the culture media than cells pretreated with ddl.
  • ddl was unable to prevent infection at any of the times studied, and ddl-treated cells were more prone to infection than untreated control cells when exposed to virus either 24 or 48 hours after drug removal. Even more striking were the increased levels of infection in AZT-treated cells when they were exposed to virus at either 24 or 48 hours following drug removal.
  • Figure 7E illustrates the results of experiments wherein NIH 3T3 cells were treated with free AZT, AE 6 C and AE 6 PC conjugates and then infected with the HgH-encoding recombinant Mo-MuLV construct. In these experiments, NIH 3T3 cells were infected with the recombinant construct for 24 hr without added drug or in the presence of 0.25mM unconjugated AZT, AE 6 C or
  • the antifolate drug methotrexate was conjugated with a variety of polar lipid carriers via organic spacer moieties having specific reactive functional groups.
  • a representative sample of such compounds is shown in Figures 8A through 8C, wherein MC represents Mtx linked to sphingosine via an amide bond to a 6-aminohexanoic acid spacer; ME 6 C represents Mtx linked to sphingosine via an ester linkage to a 6-hydroxyhexanoic acid spacer; and MSC represents Mtx linked to sphingosine via a salicylic acid ester linkage to a 6-aminohexanoic acid spacer.
  • AE 6 C 6-hydroxyhexanoic acid spacer
  • the compounds were tested for their growth inhibitory effects on murine NIH 3T3 cells growing in cell culture. About one million such cells per PI 00 tissue culture plate were grown in DMEM media supplemented with 10% fetal calf serum (GIBCO, Grand Island, NY) in the presence or absence of a growth-inhibitory equivalent of each prodrug. Cell numbers were determined after 70 hours growth in the presence or absence of the prodrug. In a second set of experiments, an amount of a brain homogenate containing an enzymatically-active esterase was included in the growth media.
  • Table III shows the results of a comparison of drug uptake and retention studies performed with AZT and the prodrug AE 6 C and with ddl and the prodrug IE 6 C.
  • Antiviral amounts (l ⁇ M AZT, AE 6 C, ddl or IE 6 C) of these compounds were added to NIH 3T3 cell cultures and incubated for 2 hr. Cells were then transferred to media (DMEM, GIBCO) without drug and incubated for an additional 24 hr. Cell samples were analyzed by radioimmunassay (RJA) at 0, 6, 12 and 24 hr after removal of drug or prodrug.
  • RJA radioimmunassay
  • both prodrugs (AE 6 C and IE 6 C) were retained in the cells to a much greater extent than free drug (for AZT, up to 35-fold higher at 12 hr and for ddl, up to 23-fold higher at 12 hours; the ratios could not be calculated for the 24 hr time point, but is estimated to be at least 64-fold and 41 -fold, respectively).
  • prodrug-polar lipid conjugates are both taken up and retained to a greater extent that free AZT or ddl in mammalian cells.
  • AZT and ddl prodrugs were also found to be significantly less toxic to hematopoietic cells than free drug.
  • the prodrug AE 6 C was much less toxic to NIH/3T3 cells in vitro and also to bone marrow erythroid (BFU-E) and myeloid (CFU-GM) hemopoietic progenitor cells of both murine and human origin.
  • BFU-E bone marrow erythroid
  • CFU-GM myeloid
  • a salicylic acid ester of methotrexate conjugated to sphingosine via a 6-amino hexanoic acid spacer termed MSC herein and illustrated in Figure 8C
  • MSC 6-amino hexanoic acid spacer
  • Figure 9A D-erythro- sphingosine was reacted at room temperature with two equivalents of tert-butyl dimethyl silyl imidazole (TBDMS) in tetrahydrofuran (THF) to yield the sphingosine derivative protected at both head group hydroxy Is with TBDMS.
  • TDMS tert-butyl dimethyl silyl imidazole
  • THF tetrahydrofuran
  • the sphingosine-salicylate conjugate produced in this reaction was then treated with sodium methoxide (NaOMe) at room temperature to remove the acetate protecting group on the salicylate phenol oxygen atom.
  • NaOMe sodium methoxide
  • Activated methotrexate was then covalently linked to this salicylate phenol group by reaction with the sphingosine-salicylate conjugate at room temperature in the presence of DMAP and CDI, forming an salicylate ester with Mtx.
  • the sphingosine head group hydroxyls were deprotected by treatment with hydrochloric acid (HCl).
  • the product of this reaction was sphingosine conjugated to a single 6-aminocaproyl salicylate at the sphingosine amino group, and having a deprotected phenol group on the salicylate moiety.
  • the sphingosine hydroxyl groups were then protected by reaction with 2,2-dimethoxypropane at room temperature in acetone and para-toluene sulfonic acid (pTsOH).
  • pTsOH para-toluene sulfonic acid
  • Activated Mtx was then conjugated in an ester linkage to the phenol group of the salicylate moiety with DMAP and CDI at 40°C.
  • the sphingosine hydroxyl groups were deprotected using trifluoroacetic acid.
  • a stock solution of tritiated Mtx was prepared by mixing 50 ⁇ L l .OmCi/mL 3 H-Mtx (obtained from DuPont, Boston, MA) with 4.95mL Buffer B (comprising 0.05M sodium phosphate, pH 7.0 and 0.2M 2-mercaptoethanol), aliquotted in lmL aliquots, and stored at 4°C in the dark until use.
  • Buffer B comprising 0.05M sodium phosphate, pH 7.0 and 0.2M 2-mercaptoethanol
  • Standard Mtx-ceramide solution was prepared by dissolving 7.3mg Mtx (98%o purity) into 7.152mL Buffer A (to a final concentration of l OOng/ ⁇ L) and stored at 4°C in the dark until use.
  • Buffer A 3 H-Mtx was diluted by the addition of 200 ⁇ L stock solution (l ⁇ Ci/l OO ⁇ L) to 5mL Buffer A.
  • the assay was performed by mixing lOO ⁇ L 3 H- Mtx, lOO ⁇ L antibody, lOO ⁇ L Mtx-ceramide standard or sample, and Buffer A to a final volume of 500 ⁇ L.
  • Controls contained Buffer A in place of antibody, Mtx- ceramide standard, or sample. The mixtures were incubated at room temperature for 50min after mixing, and then at 4°C for lOmin.
  • dextran-coated charcoal prepared by dissolving 5g Norit A charcoal and 0.5g dextran T-70 in 400mL water
  • dextran-coated charcoal was then added to each assay mixture, vortexed or otherwise thoroughly mixed, incubated at 4°C for lOmin, and then centrifuged 4°C for 15min at 2500rpm in a Beckman J-6B centrifuge (Beckman Coulter Instruments, Palo Alto, CA).
  • lOO ⁇ L of the supernatant was removed and added to 7mL scintillation fluid (Ecolume) in a scintillation vial, and the amount of radioactivity determined by liquid scintillation using a liquid scintillation counter (Beckman).
  • MSC in DMSO MSC in DMSO.
  • MSC and MTX were found at relatively equivalent levels in kidney, and MTX was present at about 10-fold excess over MSC in thymus.
  • the results from liver were similar to kidney; however, the absolute levels of MTX and MSC were much higher in liver. In fact, liver showed the highest absolute levels of MTX observed, while the absolute amount of MSC detected in liver was similar to the levels observed in spleen. In contrast to lung and spleen tissue, however, more MSC was detected in liver tissue from animals administered with the compound in FBS than in DMSO.
  • mice fed or fasted mice were administered drug or prodrug conjugates by oral intubation or intravenous injection, as described above. These results show a five- to greater than three hundred-fold increase in uptake and accumulation in mouse brain of prodrug over methotrexate alone, further demonstrating the efficacy of drug delivery to the brain using the prodrugs of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention décrit des conjugués lipidiques polaires et des procédés permettant d'effectuer l'apport et l'accumulation de composés biologiquement actifs, tels que des médicaments, dans des organes, des tissus et des cellules, notamment au niveau de sites physiologiquement protégés, à des niveaux utiles d'un point de vue pharmacocinétique. Ces conjugués lipidiques polaires permettent d'atteindre des concentrations de médicaments, notamment au niveau de ces sites physiologiquement protégés, à des niveaux auxquels ces composés sont thérapeutiquement efficaces après administration de quantités systémiques très inférieures à ce qui peut être obtenu couramment. Cette technique convient pour des médicaments, des agents et des composés antiprolifératifs, antinéoplasiques, antibiotiques, antibactériens, antimycotiques ou antiviraux, en vue d'une introduction rapide et efficace de ces agents, par exemple à travers la barrière hémato-encéphalique.
EP99935721A 1998-12-04 1999-07-20 Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques Withdrawn EP1150718A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/US98/00258 1998-12-04
PCT/US1998/025847 WO2000033883A1 (fr) 1998-12-04 1998-12-04 Conjugues lipides polaires covalents avec medicaments antimicrobiens et antineoplasiques destines a cibler des sites biologiques proteges
PCT/US1999/016361 WO2000033884A1 (fr) 1998-12-04 1999-07-20 Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques

Publications (1)

Publication Number Publication Date
EP1150718A1 true EP1150718A1 (fr) 2001-11-07

Family

ID=22268429

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99935721A Withdrawn EP1150718A1 (fr) 1998-12-04 1999-07-20 Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques

Country Status (4)

Country Link
EP (1) EP1150718A1 (fr)
AU (2) AU1628799A (fr)
CA (1) CA2353832A1 (fr)
WO (1) WO2000033883A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3033080A4 (fr) * 2013-08-15 2017-01-11 Antivirus Therapeutics Procédés et compositions pour augmenter l'efficacité d'agents antiviraux
CN108735291A (zh) * 2018-05-21 2018-11-02 上海青研科技有限公司 基于内隐测试的毒品成瘾人员毒品渴求度测评方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
WO1998003204A1 (fr) * 1996-07-23 1998-01-29 Oregon Health Sciences University Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0033884A1 *

Also Published As

Publication number Publication date
WO2000033883A1 (fr) 2000-06-15
AU1628799A (en) 2000-06-26
CA2353832A1 (fr) 2000-06-15
AU5114199A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
US6024977A (en) Covalent polar lipid conjugates with neurologically active compounds for targeting
US7045543B2 (en) Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US6387876B1 (en) Covalent polar lipid-conjugates with biologically active compounds for use in salves
Walther et al. Prodrugs in medicinal chemistry and enzyme prodrug therapies
AU620901B2 (en) Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use
US5484809A (en) Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid
AU711774B2 (en) Prodrugs of pharmaceuticals with improved bioavailability
US5194654A (en) Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US6448392B1 (en) Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US6252060B1 (en) Antiviral liponucleosides: treatment of hepatitis B
JPH07500573A (ja) 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US6599887B2 (en) Methods of treating viral infections using antiviral liponucleotides
WO2002087465A2 (fr) Compositions et methodes permettant un double ciblage d'infections virales et de cellules cancereuses
JP5031162B2 (ja) ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
CA2132608A1 (fr) Pro-promedicaments; fabrication et utilisation
US5817638A (en) Antiviral liponucleosides: treatment of hepatitis B
WO2000033884A1 (fr) Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques
EP1150718A1 (fr) Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques
WO2023047399A1 (fr) Conjugués cannabinoïdes-lipides, leurs procédés de production et leurs utilisations
AU724421B2 (en) Covalent polar lipid conjugates with biologically-active compounds for use in salves
AU738524C (en) Covalent polar lipid conjugates for targeting
WO2023047400A1 (fr) Conjugué clivable et ses utilisations
EP1754712A2 (fr) conjugués de fixation au récepteur de transcobalamine utiles pour le traitement d'une prolifération cellulaire anormale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030520